Entasis Therapeutics (ETTX) Stock Price, News & Analysis

Company Overview

Entasis Therapeutics Holdings Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibacterial products to treat serious infections caused by multidrug-resistant pathogens in the United States. Its lead product candidate is sulbactam-durlobactam (SUL-DUR), a novel IV antibiotic that is in Phase III clinical trial for the treatment of pneumonia and bloodstream infections caused by carbapenem-resistant Acinetobacter baumannii. The company also develops Zoliflodacin, a novel orally administered molecule, which is in Phase III clinical trial for the treatment of uncomplicated gonorrhea; ETX0282CPDP, an oral drug that is in Phase I clinical trial for the treatment of urinary tract infections; and ETX0462, a drug candidate from NBP platform that is in pre-clinical stage for the treatment of multidrug-resistant gram-negative infections. The company has a license and collaboration agreement with Zai Lab (Shanghai) Co., Ltd. for the development of durlobactam and SUL-DUR; and collaboration agreement with Global Antibiotic Research and Development Partnership for the development and commercialization of a product candidate zoliflodacin. Entasis Therapeutics Holdings Inc. was founded in 2015 and is headquartered in Waltham, Massachusetts. Entasis Therapeutics Holdings Inc. operates as a subsidiary of Innoviva, Inc.

Key Stats

• Today's Range: $2.19 to $2.19
• 50-Day Range: $2.18 to $2.20
• 52-Week Range: $1.40 to $3.88
• Volume: 800 shs
• Average Volume: 239,104 shs
• Market Capitalization: $104.80 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

ETTX Stock Analysis - Frequently Asked Questions

How were Entasis Therapeutics' earnings last quarter?

Entasis Therapeutics Holdings Inc. (NASDAQ:ETTX) released its earnings results on Thursday, November, 4th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.26).

When did Entasis Therapeutics IPO?

Entasis Therapeutics (ETTX) raised $75 million in an IPO on Wednesday, September 26th 2018. The company issued 4,400,000 shares at a price of $16.00-$18.00 per share. Credit Suisse and BMO Capital Markets served as the underwriters for the IPO and SunTrust Robinson Humphrey and Wedbush PacGrow were co-managers.

What other stocks do shareholders of Entasis Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Entasis Therapeutics investors own include Sorrento Therapeutics (SRNE), VYNE Therapeutics (VYNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), CymaBay Therapeutics (CBAY), Dynavax Technologies (DVAX) and Pfizer (PFE).

Company Calendar

• Last Earnings: 11/04/2021
• Today: 12/21/2024
• Fiscal Year End: 12/31/2024

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: NASDAQ:ETTX
• CUSIP: N/A
• CIK: 1724344
• Web: www.entasistx.com
• Phone: (781) 810-0120
• Fax: N/A
• Employees: 51
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.12)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-47,140,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -145.48%
• Return on Assets: -103.75%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 1.65
• Quick Ratio: 1.65

Sales & Book Value

• Annual Sales: $7 million
• Price / Sales: 14.97
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.66 per share
• Price / Book: 3.32

Miscellaneous

• Outstanding Shares: 47,852,000
• Free Float: 44,742,000
• Market Cap: $104.80 million
• Optionable: Not Optionable
• Beta: 1.33